Trials / Not Yet Recruiting
Not Yet RecruitingNCT06884059
Time Restricted Eating in Patients With Microalbuminuria
Impact of Time-Restricted Eating (TRE) on Kidney Health (The TREK Study)
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- Sponsor
- University of California, San Diego · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a clinical trial to assess how time-restricted eating (TRE) may improve kidney health and filtration patients with type 2 diabetes and increased protein content in their urine. All participants will be participating in TRE in which they follow a consistent 8-10 hour eating window everyday.
Detailed description
The proposed study aims to address the unmet medical need of treating microalbuminuria, particularly in patients with diabetes, through a prospective single-arm intervention lasting twelve weeks. Microalbuminuria, indicative of abnormal glomerular capillary permeability, serves as an early marker for renal impairment and heightened cardiovascular risk. The study hypothesizes that adherence to time-restricted eating (TRE) over the intervention period will significantly reduce microalbuminuria levels, as assessed by the urine albumin-to-creatinine ratio (uACR). Unlike other methods, uACR provides an estimation of 24-hour urine albumin excretion and is unaffected by variations in urine concentration, eliminating the need for timed specimens or 24-hour collections. If successful, this study could highlight the potential of TRE as a non-invasive and accessible dietary intervention for managing microalbuminuria and related conditions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Time Restricted Eating | Participants in the TRE group with continue to follow their physicians treatment plan for type II diabetes mellitus and consume all of their food within an 8-10 hour eating window. |
Timeline
- Start date
- 2025-03-01
- Primary completion
- 2027-02-01
- Completion
- 2028-02-01
- First posted
- 2025-03-19
- Last updated
- 2025-03-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06884059. Inclusion in this directory is not an endorsement.